CENTER FOR DRUG EVALUATION AND RESEARCH

Thursday, October 28, 2004

Office of New Drugs

Program Management Team
(HFD-022)
Eldridge Coles
301-443-5177
FAX 301-827-6707

Pregnancy Labeling Team
(HFD-020)
Kathleen Uhl
301-594-3937
FAX 301-443-5515

Office of New Drugs (HFD-020)
John Jenkins, MD
301-594-3937
FAX 301-480-8329
Sandra Kweder
Deputy Director

Office of Drug Evaluation VI
(HFM-500)
Karen D. Weiss, MD
301-827-5098
FAX 301-827-5395

Division of Therapeutic Biological Internal Medicine Products (HFM-576)
Marc K. Walton, MD
301-827-5096
FAX 301-827-5394

Division of Review Management and Policy (HFM-585)
Earl Dye, PhD (Actg)
301-827-5099
FAX 301-827-5397

Division of Therapeutic Biological Oncology Products (HFM-573)
Patricia Keegan, MD
301-827-5093
FAX 301-827-2801

Study Endpoints and Labeling Dev. (HFD-020)
Laurie Burke
301-594-3937
FAX 301-443-5515

Pharmacology/Toxicology Staff
(HFD-024)
David Jacobson-Kram, PhD
301-594-2569
FAX 301-480-8329

Office of Drug Evaluation I
(HFD-101)
Robert Temple, MD (Actg)
301-594-6758
FAX 301-594-5298

Division of Neuropharmacological Drug Products (HFD-120)
Russell Katz, MD
301-594-2850
FAX 301-594-2859

Division of Oncology Drug Products (HFD-150)
Richard Pazdur, MD
301-594-2473
FAX 301-594-0498

Division of Cardio-Renal Drug Products (HFD-110)
Norman Stockbridge, MD (Actg)
301-594-5300
FAX 301-594-5495

Office of Drug Evaluation II
(HFD-102)
Robert Meyer, MD
301-827-5920
FAX 301-480-6644

Division of Metabolic and Endocrine Drug Products (HFD-510)
David Orloff, MD
301-827-6430
FAX 301-443-9282

Division of Pulmonary Drug Products (HFD-570)
Badrul Chowdhury, MD
301-827-1050
FAX 301-827-1271

Division of Anesthetic, Critical Care and Addiction Drug Products (HFD-170)
Bob Rappaport, MD
301-827-7410
FAX 301-443-7068

Office of Drug Evaluation III
(HFD-103)
Florence Houn, MD
301-827-3144
FAX 301-480-3761

Division of GastroIntestinal Coagulation Drug Products (HFD-180)
Robert Justice, MD
301-827-7310
FAX 301-443-9285

Division of Reproductive and Urologic Drug Products (HFD-580)
Daniel Shames, MD
301-827-4260
FAX 301-827-4267

Division of Medical Imaging and Radiopharmaceutical Drug Products (HFD-160)
George Q Mills, MD
301-827-7510
FAX 301-443-9281

Office of Drug Evaluation IV
(HFD-104)
Mark Goldberger, MD, M.P.H
301-827-2350
FAX 301-827-2520

Drug Shortages Program

Antimicrobial Resistance Initiative

Division of Anti-Infective Drug Products (HFD-520)
Janice Soreth, MD
301-827-2120
FAX 301-827-2325

Division of Anti-Viral Drug Products (HFD-530)
Debra B. Birnkrant, MD
301-827-2330
FAX 301-827-2523

Division of Special Pathogen and Immunologic Drug Products (HFD-590)
Renata Albrect, MD
301-827-2336
FAX 301-827-2510

Office of Drug Evaluation V
(HFD-105)
Jonca Bull, MD
301-827-2250
FAX 301-827-2317

Botanical Review Team

Division of Anti-Inflammatory Analgesic and Ophthalmologic Drug Products (HFD-550)
Brian Harvey, MD, PhD (Actg)
301-827-2040
FAX 301-827-2531

Division of Dermatologic and Dental Drug Products (HFD-540)
Jonathan Wilkin, MD
301-827-2021
FAX 301-827-2075

Division of Over-the-Counter Drug Products (HFD-560)
Charles Ganley, MD
301-827-2222
FAX 301-827-2315